Glenmark Life Sciences Ltd

GLS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7,673 cr, stock is ranked 388
Low RiskStock is 1.59x as volatile as Nifty
626.251.75 (+0.28%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7,673 cr, stock is ranked 388
Low RiskStock is 1.59x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
21.83
PB RatioPB Ratio
10.19
Dividend YieldDiv. Yield
Sector PESector PE
38.74
Sector PBSector PB
5.18
Sector Div YldSctr Div Yld
0.66%

Forecast & RatingsDetailed Forecast 

67%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Glenmark Life Sciences Ltd is a manufacturer of pharmaceutical preparation. The Company was founded in June 2011 and is located in Solapur, India.

Investor PresentationView older 

Nov 10, 2021

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

20182019202020210.000.891.551.89-0.000.200.310.35
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 17.16%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

See detailed holdings

Recent EventsAll events 

Monitoring Agency Report 
Announced OnNov 13, 2021

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report dated November 12, 2021 issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 30th September, 2021 in respect of utilization of proceeds of the IPO of the Company.This is for your information and record. | Download

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report dated November 12, 2021 issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 30th September, 2021 in respect of utilization of proceeds of the IPO of the Company.This is for your information and record. | Download

Investor Presentation 
Announced OnNov 10, 2021

Glenmark Life Sciences Limited has informed the Exchange about Investor Presentation | Download

Glenmark Life Sciences Limited has informed the Exchange about Investor Presentation | Download

Cash Dividend 
Ex. DateNov 22, 2021

Interim • Div/Share: ₹ 10.5

See all events